Creative Medical Technology Holdings, Inc. (CELZ)
Nasdaq · Healthcare · Biotechnology
$0.92−2.79%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $7.0M
- 52-week range
- $0.62 – $6.25
- 52-week change
- −72.25%
- EPS (trailing)
- −$2.07
Fiscal year to Dec 2025
- Revenue
- $6K (−45.45%)
- Net income
- −$6.0M
- Operating margin
- −102380.0%
- Diluted EPS
- −$2.52
From the company’s annual report on SEC EDGAR.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.
Headquarters: Phoenix, United States · 4 employees · creativemedicaltechnology.com